Behavioural Outcome in Children with Congenital Adrenal Hyperplasia: Experience of a Single Centre

Table 1

Disease characteristics of CAH cases.

	Male 𝑁=20	Female 𝑁=29
Age (in months) at starting treatment^a	1.0 (1.5)	0.5 (0.6)
Age in years at study entry	11.6 (4.3)^a	11.9 (3.4)^a
	11.5 (6–18)^b	12.0 (6–17)^b
Presentation at diagnosis
Salt wasting features^c	17 (85)	23 (79)
No salt wasting features^c	3 (15)	6 (21)
Ambiguous genitalia^c	0	29 (100)
Hypertension^c	0	0
Height SDS at the time of CBCL^a	−1.1 (1.6)	−1.4 (2.2)
Serum 17-OHP in nmol/L at the time of CBCL^a	46.0 (182.1)	8 (131.1)
Glucocorticoid dose in mg/m^2/day near the time of CBCL^a	17.3 (4.9); (CI: 15–19.6)	14.4 (2.4); (CI: 13.9–15.7)
Prader rating^c
1		4 (14)
2		8 (28)
3		14 (48)
4		3 (10)
Genitoplasty^c
Nil		4 (14)
Clitoroplasty		11 (38)
Clitoroplasty and vaginoplasty		14 (48)
Age in years at the first genitoplasty^a		2.3 (2.7)
Serum testosterone in nmol/L of CAH girls at the time of CBCL^a		0.7 (3.3)

aMean (standard deviation).
^bMedian (range).
^cFrequency (%).
CI: confidence interval.